Boston Scientific Corp.

Boston Scientific Corp. saw a significant stock decline today, despite strong financial indicators. The company reported a 12.73% annual increase in net sales, with operating cash flow reaching USD 4,285 million. Its market capitalization stands at USD 120,852 million, reflecting a solid position in the retailing industry.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a significant decline in stock performance. The company, with a market capitalization of USD 120.85 billion, has a P/E ratio of 36.00 and a moderate debt-to-equity ratio of 0.39, indicating its financial positioning.

Boston Scientific Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 120.85 billion, maintains a P/E ratio of 36.00 and a debt-to-equity ratio of 0.39, indicating solid financial health.

Boston Scientific Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year, contrasting sharply with the S&P 500's gains. The company, with a market cap of USD 121,935 million, shows moderate leverage and a notable return on equity.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a significant stock price decline. The company, valued at approximately USD 121.9 billion, has a P/E ratio of 36.00 and a moderate debt-to-equity ratio of 0.39, focusing on reinvesting earnings.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a significant decline in stock performance. The company, valued at approximately USD 121.9 billion, has a P/E ratio of 36.00 and a debt-to-equity ratio of 0.39, indicating low debt levels. Its return on equity stands at 13.88%.

Boston Scientific Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 121.9 billion, maintains a P/E ratio of 36.00 and a debt-to-equity ratio of 0.39, indicating financial stability.

Boston Scientific Corp. has reached a new 52-week low, reflecting a significant decline in its stock value over the past year. The company, with a market capitalization of approximately USD 121.94 billion, exhibits a P/E ratio of 36.00 and a moderate debt-to-equity ratio of 0.39, highlighting its financial health.

Boston Scientific Corp. has hit a new 52-week low, with its stock price declining significantly over the past year. The company, with a market capitalization of approximately USD 121.9 billion, operates in the retailing industry and exhibits a price-to-earnings ratio of 36.00 and a return on equity of 13.88%.

Boston Scientific Corp. has reached a new 52-week low, reflecting a significant decline in its stock performance over the past year. The company, with a market capitalization of approximately USD 121.9 billion, maintains a P/E ratio of 36.00 and a low debt-to-equity ratio of 0.39, indicating solid financial health.

Boston Scientific Corp. saw its stock decline significantly today, contrasting with a slight increase in the S&P 500. Over the past month, the company has faced challenges, with a notable year-to-date drop. Despite this, it holds a strong market position and demonstrates healthy long-term growth metrics.

Boston Scientific Corp. faced a significant stock decline today, contrasting with the S&P 500's gains. Over the past month, the company has seen a notable drop, with annual performance down substantially. Despite these challenges, Boston Scientific has shown long-term growth, with strong sales and solid financial metrics.

Boston Scientific Corp. saw a notable increase in stock performance on April 22, 2026, reaching an intraday high. Despite facing year-to-date and one-year declines, the company has shown resilience over three years. Key financial metrics include strong operating cash flow and net sales, underscoring its operational capabilities.

Boston Scientific Corp. experienced a strong opening, significantly outperforming the S&P 500. The company reported quarterly net sales of USD 5,061 million, with a 12.73% annual growth rate and robust operating cash flow of USD 4,285 million. Its fundamentals remain solid, despite some bearish technical indicators.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a notable decline in stock performance. The company, with a market capitalization of USD 121.9 billion, has a P/E ratio of 36.00 and a low debt-to-equity ratio of 0.39, indicating financial stability.

Boston Scientific Corp. has reached a new 52-week low of USD 60.59, reflecting a one-year decline of 20.85%. The company, with a market capitalization of approximately USD 121.94 billion, has a P/E ratio of 36.00 and a debt-to-equity ratio of 0.39, indicating moderate debt levels.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a significant stock decline. The company, valued at approximately USD 121.9 billion, has a P/E ratio of 36.00 and a debt-to-equity ratio of 0.39, indicating a conservative leverage approach. Its return on equity stands at 13.88%.

Boston Scientific Corp. has hit a new 52-week low, with a notable decline in its stock price and a 1-year performance decrease. The company, categorized as large-cap with a market capitalization of USD 130,304 million, faces challenges in the current market, contrasting with the S&P 500's strong performance.

Boston Scientific Corp. has reached a new 52-week low, reflecting a challenging year with a decline in performance compared to the S&P 500. The company has a market capitalization of USD 130,304 million, a P/E ratio of 69.00, and a return on equity of 13.88%, indicating effective management.